https://scholars.lib.ntu.edu.tw/handle/123456789/434871
標題: | Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan | 作者: | Yang, Che-Wen YUNG-TSU CHO CHIA-YU CHU |
關鍵字: | Chronic spontaneous urticaria;Efficacy;Maintenance treatment;Omalizumab;Safety | 公開日期: | 2017 | 出版社: | Elsevier Ltd | 卷: | 35 | 期: | 4 | 起(迄)頁: | 182-186 | 來源出版物: | Dermatologica Sinica | 摘要: | Background/Objectives Accumulating evidence has shown that omalizumab is an effective and safe treatment for chronic spontaneous urticaria (CSU), but there is little information regarding the use of omalizumab to treat CSU in Taiwan. Reports on clinical experiences with using omalizumab for CSU for more than 6 months are also lacking. Methods A retrospective review of medical records of consecutive CSU patients receiving omalizumab treatment in the Urticaria Special Clinic of one tertiary referral center in Taiwan was conducted. We analyzed clinical features of the patients, treatment efficacy and safety, and also long-term outcomes after omalizumab treatment. An Urticaria Activity Score over 7 days (UAS7) was recorded at each visit. Results A total of 17 CSU patients were identified (11 females and 6 males, age range: 21–83 years) with a baseline mean UAS7 of 29.8 ± 8.9 despite antihistamine treatment. All patients were treated with at least 3 doses of monthly subcutaneous injections of omalizumab. Fifteen patients achieved a UAS7 of 6 or less after 3 doses of monthly omalizumab injections. Seven of those 15 patients received an additional 1 to 3 doses and all ended up with a UAS7 of less than 2 at the 24-week follow-up. A sustained response to maintenance treatment after 24 weeks was observed in 5 patients with individual tailoring of treatment duration and dosing interval. Conclusion Omalizumab is an effective and safe treatment for antihistamine refractory CSU. Maintenance therapy with individual tailoring of the treatment duration and interval is possible. ? 2017 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028089663&doi=10.1016%2fj.dsi.2017.05.003&partnerID=40&md5=ef1fbdc9f380b40c4315498b6f6f94e3 https://scholars.lib.ntu.edu.tw/handle/123456789/434871 |
ISSN: | 1027-8117 | DOI: | 10.1016/j.dsi.2017.05.003 | SDG/關鍵字: | buclizine; cetirizine; cyproheptadine; desloratadine; dexchlorpheniramine; dexchlorpheniramine maleate; doxepin; fexofenadine; hydroxychloroquine; hydroxyzine; immunoglobulin E; ketotifen; levocetirizine; omalizumab; oxazolam; prednisolone; salazosulfapyridine; add on therapy; adult; aged; angioneurotic edema; Article; blood autotransfusion; case study; chronic urticaria; chronopharmacology; clinical article; clinical feature; clinical outcome; corticosteroid therapy; disease duration; disease severity assessment; dose response; drug dose reduction; drug efficacy; drug safety; female; follow up; human; immunoglobulin blood level; injection site induration; injection site pain; maintenance therapy; male; medical record review; middle aged; nausea; personalized medicine; remission; retrospective study; skin disease assessment; systemic therapy; Taiwan; Taiwanese; tertiary care center; treatment duration; treatment response; Urticaria Activity Score; very elderly; young adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。